138 results on '"Bachas, Costa"'
Search Results
2. Immunophenotypic features of early haematopoietic and leukaemia stem cells.
3. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
4. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
5. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry
6. P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
7. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
8. P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML
9. Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?
10. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
11. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
12. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry
13. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
14. Prospective validation of the prognostic relevance of CD34$^{+}$CD38$^{-}$ AML stem cell frequency in the HOVON-SAKK132 trial
15. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
16. Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death
17. Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
18. Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
19. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
20. AML-348 Impact of Hemodilution on Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia
21. Impact of Hemodilution on Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia
22. Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection
23. Erratum:Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party (HemaSphere (2022) 6:1 (e676) DOI: 10.1097/HS9.0000000000000676)
24. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia:An outcome- and cost-analysis
25. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
26. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry.
27. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry
28. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication
29. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
30. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
31. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
32. Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes
33. Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10)
34. Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse
35. Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes
36. Procedures for the expansion of CD14+ precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy
37. Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia
38. Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
39. TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia
40. TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.
41. Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies
42. Impact of Hemodilution on Measurable Residual Disease Measured Via Flow-Cytometry in Acute Myeloid Leukemia Analyzed Using Subsequent Pulls
43. The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia
44. Gene Expression Profiles Associated with Pediatric Relapsed AML
45. Procedures for the expansion of CD14+precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy
46. Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML
47. Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.
48. Abstract 3209: Gene expression micro array analysis of diagnosis and matched relapse pediatric AML samples indicates that immune regulatory pathways and epigenetic factors are involved in disease progression
49. Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse
50. Abstract A3: Low-frequency subclones in acute myeloid leukemia samples at diagnosis indicate oligoclonality and may play a role in disease progression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.